Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142310 · ClinicalTrials.gov registry record · Phase 4
Reversing Corticosteroid Induced Memory Impairment
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT01142310 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 54 participants.
The verdict
NCT01142310, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
Medically stable outpatients receiving chronic oral corticosteroid therapy were enrolled in a 48-week randomized, double-blind, placebo-controlled, parallel-group, trial of lamotrigine.
Interventions
- DRUG Placebo
- DRUG Lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142310
The ClinicalTrials.gov registry entry for NCT01142310 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01142310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142310 about?
NCT01142310 is a clinical study titled "Reversing Corticosteroid Induced Memory Impairment". Medically stable outpatients receiving chronic oral corticosteroid therapy were enrolled in a 48-week randomized, double-blind, placebo-controlled, parallel-group, trial of lamotrigine.
What is the current status of trial NCT01142310?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2010-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01142310?
The interventions under investigation include: Placebo (DRUG), Lamotrigine (DRUG).
Who is sponsoring clinical trial NCT01142310?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.